Role of primary hyperaldosteronism in the development of arterial hypertension

Authors

Keywords:

HYPERTENSION, ALDOSTERONE, HYPERALDOSTERONISM.

Abstract

Introduction: primary hyperaldosteronism is considered the most frequent secondary endocrine form of arterial hypertension; it is characterized by an inadequate elevation of aldosterone due to an autonomous and independent production of the renin-angiotensin-aldosterone system.

Objective: to describe the role of primary hyperaldosteronism in the development of arterial hypertension.

Methods: a search for information was carried out in the PubMed/MedLine, Scopus and SciELO databases. A search strategy was structured using the terms hypertension and hyperaldosteronism.

Results: primary hyperaldosteronism is an entity considered as the first cause of secondary arterial hypertension; however, it is underdiagnosed due to the lack of knowledge, causing a large number of patients with hypertension to present resistance to the usual treatment, producing an increase in cardiovascular, metabolic, renal and cerebrovascular risk in the patient.

Conclusions: screening of the hypertensive patient is of great importance for the timely detection of primary hyperaldosteronism and its laterization, since it allows guiding an adequate treatment, either pharmacological or surgical, to guarantee the reduction or control of blood pressure, cardiovascular and renal risk and the appearance of diabetes mellitus in the patient in order to improve his quality of life.

Downloads

Download data is not yet available.

References

1. Parra Ramírez P, Martín Rojas-Marcos P, Cuesta Hernández M, Ruiz-Sánchez JG, Lamas Oliveira C, Hanzu FA, et al. Primera encuesta sobre el diagnóstico y tratamiento del hiperaldosteronismo primario por especialistas españoles en Endocrinología y Nutrición. Endocrinol Diabetes y Nutr [Internet]. 2023 [citado 06/06/2023]; 70(6):374–80. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S2530016422001070

2. Lee FT, Elaraj D. Evaluation and Management of Primary Hyperaldosteronism. Surg Clin North Am [Internet]. 2019 [citado 06/06/2023]; 99(4):731–45. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0039610919300362

3. Ribas A, Chillarón JJ, Vázquez S, Carrera MJ, Martínez-Ruiz N, Galcerán I, et al. Indicación, realización y resultado del cateterismo de venas adrenales en pacientes con hiperaldosteronismo primario. Nefrología [Internet]. 2022 [citado 06/06/2023]; [InPress]. Disponible en: https://www.sciencedirect.com/science/article/pii/S0211699522001588

4. Vaidya A, Carey RM. Evolution of the Primary Aldosteronism Syndrome: Updating the Approach. J Clin Endocrinol Metab [Internet]. 2020 [citado 06/06/2023]; 105(12): 3771–83. Disponible en: https://academic.oup.com/jcem/article/105/12/3771/5899581

5. Reincke M, Bancos I, Mulatero P, Scholl UI, Stowasser M, Williams TA. Diagnosis and treatment of primary aldosteronism. Lancet Diabetes Endocrinol [Internet]. 2021 [citado 06/06/2023]; 9(12): 876–92. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S2213858721002102

6. Vélez J, Vélez Páez P, Aguayo Moscoso S, Navarrete Aráuz R, Tercero Martínez W, López Rondón E, et al. Endocrinología crítica de las glándulas suprarrenales y el eje hipotálamo hipofisario adrenal. Rev Cien Ecu [Internet]. 2019 [citado 06/06/2023]; 1(4):1–10. Disponible en: http://www.cienciaecuador.com.ec/index.php/ojs/article/view/5

7. Monge A, Echeverri Lohrengel A, Leiva Rojas DF, Soto Rivera P, Salas Fernandez MJ. Fisiopatología y presentación clínica del hiperaldosteronismo primario. Rev Cienc y Salud Integr Conoc [Internet]. 2021 [citado 06/06/2023]; 5(3): e292. Disponible en: http://revistacienciaysalud.ac.cr/ojs/index.php/cienciaysalud/article/view/292

8. El-Asmar N, Rajpal A, Arafah BM. Primary Hyperaldosteronism. Med Clin North Am [Internet]. 2021 [citado 06/06/2023]; 105(6): 1065-80. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0025712521000936

9. Pérez F. Adenoma suprarenal productor de aldosterona: reporte de un caso de hiperaldosteronismo primario. Rev Médico Científica [Internet]. 2020 [citado 06/06/2023]; 33(1): 1–7. Disponible en: https://www.revistamedicocientifica.org/index.php/rmc/article/view/536

10. Mulatero P, Monticone S, Deinum J, Amar L, Prejbisz A, Zennaro M-C, et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J Hypertens [Internet]. 2020 [citado 06/06/2023]; 38(10):1919–28. Disponible en: https://journals.lww.com/10.1097/HJH.0000000000002510

11. Ahmed S, Hundemer GL. Benefits of Surgical Over Medical Treatment for Unilateral Primary Aldosteronism. Front Endocrinol (Lausanne) [Internet]. 2022 [citado 06/06/2023]; 13(2022): 861581. Disponible en: https://www.frontiersin.org/articles/10.3389/fendo.2022.861581/full

12. Young WF. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med [Internet]. 2019 [citado 06/06/2023]; 285(2):126–48. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/joim.12831

13. Valdivia S, Mora F, Genskowsky K, Novik V. Consideraciones diagnósticas actuales sobre el hiperaldosteronismo primario. Bol Hosp Viña del Mar [Internet]. 2020 [citado 06/06/2023]; 76(2-3):72-7. Disponible en: https://pesquisa.bvsalud.org/portal/resource/pt/biblio-1398038

14. Zennaro M-C, Boulkroun S, Fernandes-Rosa FL. Pathogenesis and treatment of primary aldosteronism. Nat Rev Endocrinol [Internet]. 2020 [citado 06/06/2023]; 16(10):578–89. Disponible en: https://www.nature.com/articles/s41574-020-0382-4

15. Araujo-Castro M, Bengoa Rojano N, Fernández Argüeso M, Pascual-Corrales E, Jiménez Mendiguchía L, García Cano AM. Riesgo cardiometabólico en pacientes con hiperaldosteronismo primario y secreción autónoma de cortisol. Estudio de casos y controles. Med Clin (Barc) [Internet]. 2021 [citado 06/06/2023]; 157(10):473–9. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0025775320306278

Downloads

Published

2023-12-20

How to Cite

1.
Altamirano-Guerrero OE, López-Barrionuevo CG, Salazar-Pullutacsi KD. Role of primary hyperaldosteronism in the development of arterial hypertension. Rev Ciencias Médicas [Internet]. 2023 Dec. 20 [cited 2025 Aug. 29];27:e6291. Available from: https://revcmpinar.sld.cu/index.php/publicaciones/article/view/6291

Issue

Vol. 27 (2023): (Sistema de Publicación Continua)

Section

REVIEW ARTICLES

License

Authors who have publications with this journal agree to the following terms: Authors will retain their copyrights and grant the journal the right of first publication of their work, which will be publication of their work, which will be simultaneously subject to the Creative Commons Attribution License (CC-BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.

Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g.: deposit it in an institutional telematic archive or publish it in a volume). Likewise, and according to the recommendations of the Medical Sciences Editorial (ECIMED), authors must declare in each article their contribution according to the CRediT taxonomy (contributor roles). This taxonomy includes 14 roles, which can be used to represent the tasks typically performed by contributors in scientific academic production. It should be consulted in monograph) whenever initial publication in this journal is indicated. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which may produce interesting exchanges and increase citations of the published work. (See The effect of open access). https://casrai.org/credit/